Second Quarter Earnings Season Heats Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
You may also be interested in...
Novartis Purchases Bristol's Consumer Business
The $660 mil. acquisition makes the Swiss firm a "more attractive" Rx-to-OTC switch partner, Novartis Consumer Health CEO Choffat says. Bristol's OTCs include Excedrin, Comtrex, Bufferin, No-Doz.
IMS Health To Be Acquired By Market Research Firm VNU
Acquisition of IMS Health will allow Netherlands-based VNU to move its health care marketing segment into physician targeting. The $7 bil. deal is expected to close in the first quarter of 2006.
House Appropriations Subcommittee Plans FDA Hearing July 26
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.